Long-Term Bimekizumab Safety Data
MedPage Today
Recent News
Adverse effects from bimekizumab through 2 years or more of treatment for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) were about as expected from shorter-term data, results from long-term extension studies indicated.Read Article
Predictors of Response in Lupus
A systematic review suggests that traditional measures (serologies and disease activity) are superior to biomarkers in predicting response to biologics in systemic lupus erythematosus (SLE) patients.
Hydralazine and the Rare Risk of Vasculitis
Since the 1980s, hydralazine has been a notable cause of drug-induced lupus, and inferred to cause vasculitis as well. A retrospective cohort study from Canada has shown that vasculitis resulting from hydralazine is possible, but https://t.co/ewqCesatbm
Dr. John Cush @RheumNow ( View Tweet)
2025 Update: EULAR Recommendations on Rheumatoid Arthritis Management
EULAR has updated its RA management recommendations, notably with fewer recommendations (a total of 9, down from 11 in the 2022 version), by merging and removing previous recommendations. https://t.co/7SCIL2Prjw
Dr. John Cush @RheumNow ( View Tweet)
Urinary biomarkers improve w/ anifrolumab in TULIP-LN (lupus nephritis) trial; 112 pts, 197 uriniary proteins assessed. Urinary CD163 and MCP-1 signif improved as early as wk 12. Anifrolumab reduced the proteomic inflammatory signature, regardless of responder status https://t.co/n6fIJVDCN1
Dr. John Cush @RheumNow ( View Tweet)
SOLSTICE: phase 3b RCT of IL-23i, guselkumab vs PBO in 451 active PsA pts (GUS q4wk vs q8wk vs PBO). @wk 24 GUS signif better than PBO-ACR20 (59%/62% vs 35%), ACR50 (31%/32% vs 12%), ACR70 (17%/17% vs 2%), PASI 90 (49%/45% vs 12%), MDA (19%/24% vs 5%) ction) https://t.co/QDMCnGdN6J
Dr. John Cush @RheumNow ( View Tweet)
Pilot phase I open-label trial of the PPARγ agonist pioglitazone (ACTOS; 45 mg/d) in 13 pts w/ inclusion body myositis (IBM) showed promise. After 32 weeks, no clinical improvement but proteomic muscle metabalomics & PPARGC1A expression improved. https://t.co/MtiTnwRfaE https://t.co/jUthouMSnP
Dr. John Cush @RheumNow ( View Tweet)
FDA Approves Icotrokinra for Plaque Psoriasis
Today the FDA approved an oral IL-23 inhibitor, icotrokinra (Icotyde), for use in moderate-to-severe plaque psoriasis in adults and children 12 years of age and older (who weigh at least 40 kg) who are candidates for systemic therapy or phototherapy.
Read Article
Single center prospective cohort study of 137 Takayasu’s arteritis (TAK) pts found the prevalence of coronary arteritis was 13 (9%). TAK coronary arteritis pts were not distinguished by demographics, angiographic patterns. 50% had complications from vascular grafts or stents https://t.co/xRR7TSi5FW
Dr. John Cush @RheumNow ( View Tweet)
JAMA Patient Education Page on JAMA Eosinophilic Fasciitis (EF). EF is rare, but begins with swelling and redness of the arms and/or legs. Later the skin thickens and develops the peau d' orange appearance. EF does not involve fingers or toes, & doesnt have Raynauds https://t.co/azH9bMRsOb
Dr. John Cush @RheumNow ( View Tweet)
REVEAL, a 5-yr real-world study of 236 SLE pts initiating anifrolumab (basekbube SLEDAI-2K 7 for mucocutaneous (67%) & MSK (49%) dz. At 6 months, 26% achieved remission, 66% reached LLDAS, and 57% achieved LLDAS5. Authors claim rapid onset of action https://t.co/16OQatOcPj https://t.co/YmS2dRolL1
Dr. John Cush @RheumNow ( View Tweet)
Pitfalls of autoimmune serologic testing
Misuse of laboratory testing may lead to misdiagnoses and mismanagement; this is particulary prevalent when clinicians consider the use of the diagnostic use of serological autoimmune markers.
https://t.co/VKosO3bVL2 https://t.co/4FTvTcrGJa
Dr. John Cush @RheumNow ( View Tweet)
Worldwide Trends in Hyperuricemia
A Lancet Rheumatology systematic review shows the prevalence of hyperuricaemia has risen markedly over the past two decades in both men and women, owing to population growth, aging, and increasing age-specific rates.
https://t.co/qXx2tLcj8b https://t.co/bQ861Hkcb8
Dr. John Cush @RheumNow ( View Tweet)
Cross-sectional study of 180 PMR pts compared dz activity by PMR-AS to Systemic Immune-Inflammation Index (SII = Plts × PMNs/Lymphs) using CBC.48% had mod-hi dz (PMR-AS >=7). SII had moderate correlation with PMR-AS (r = 0.47), possibly useful in monitoring PMR https://t.co/vG1alSdVRU
Dr. John Cush @RheumNow ( View Tweet)
Hydralazine and the Rare Risk of Vasculitis
Since the 1980s, hydralazine has been a notable cause of drug-induced lupus, and inferred to cause vasculitis as well. A retrospective cohort study from Canada has shown that vasculitis resulting from hydralazine is possible, but rare.
FDA has approved secukinumab (Cosentyx) for use pediatric patients (aged >12yrs) with moderate to severe hidradenitis suppurativa https://t.co/G1BtS15sWT
Dr. John Cush @RheumNow ( View Tweet)
Is BMI a risk factor for Palindromic rheumatism (PR)? Study of 147 PR patients and 294 matched HCs. No significant difference was observed in mean BMI between PR patients and HCs and overweight or obesity was not associated with an increased risk of PR. https://t.co/W7XehFVCTR https://t.co/YRPOeqR04j
Dr. John Cush @RheumNow ( View Tweet)
ILD found in 3% of #PsA pts. Metanalysis of 6 studies, 14,272 pts found ILD pooled prevalence was 3% in PsA; highers ((6%) in studies w/ CT, HRCT. Smoking was a signif. risk factor for ILD in PsA (OR 2.94, 95% CI: 1.22–7.12; I2 = 1.8%). https://t.co/9mY4Eiqc9d
Dr. John Cush @RheumNow ( View Tweet)
A multi-center, retrospective chart review of 82 Still's disease pts (63% female; mean Dx age 6.4 ± 4 yrs; F/U ~2.8 yrs). When analyzing Dz course, 34% were monophasic, 46% polyphasic (higher-than-expected), 19.5% persistent Dz. non-monophasic predicted by active 3 mos from Dx https://t.co/qtONtpeA22
Dr. John Cush @RheumNow ( View Tweet)
FDA has accepted the supplemental biologics license application for use of interleukin-23 inhibitor tildrakizumab (Ilumya; Sun Pharma) in active psoriatic arthritis (PsA) in adults. https://t.co/cwqz9DoWsL https://t.co/fN8pbWtmfT
Links:
Dr. John Cush @RheumNow ( View Tweet)
Video
From the Blog
Podcasts
Poets Know It (3.13.2026)-
UBER Rheumatology Ride (3.6.2026)
-
UBER Rheumatology Ride (3.6.2026)
Early Decisions and Impact: Risankizumab in Bio-Naive Patients With PsA Sponsored by AbbVie Medical Affairs + Health Impact
Therapeutic Updates
5-Year Results of an IL-23 Inhibitor in Patients With PsA
Sponsored by AbbVie Medical Affairs + Health Impact
Dr. Alvin Wells and Dr. Shikha Singla share their clinical perspectives on using an IL–23 inhibitor to manage patients with PsA throughout their treatment journey in the context of 5-year data from the KEEPsAKE trial program.
Read Post
Poster Hall
